🇺🇸 FDA
Patent

US 7625563

Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids

granted A61KA61K2039/505A61K39/395

Quick answer

US patent 7625563 (Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids) held by The Board of Regents of the University of Texas System expires Mon Nov 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
43
CPC classes
A61K, A61K2039/505, A61K39/395, A61K39/39558, A61K47/62